This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older.

Study details include:

• The study duration will be up to 12 months per participant.
• The treatment duration will be up to 24 weeks.
• The number of visits will be 7.

Inclusion Criteria:

• Male or female patients at least 12 years of age inclusive, at the time of signing the informed consent
• Participants who had an allogeneic hematopoietic cell transplantation (HCT)
• Previously received at least 2 prior lines of systemic therapy for cGVHD
• Received glucocorticoid therapy with a stable dose over the 2 weeks prior to screening
• Had persistent cGVHD manifestations and systemic therapy was indicated
• Karnofsky (if aged ≥ 16 years)/Lansky (if aged <16 years) Performance Score of ≥ 60
• Capable of giving signed informed consent as described in the protocol

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Absolute neutrophil count ≤1.5 X 109/L
• Platelet count ≤ 50 X 109/L
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 3 X upper limit of normal (ULN) (>5 × ULN if due to cGVHD)
• Total bilirubin ≥ 1.5 X ULN
• Glomerular filtration rate (GFR) ≤ 30 mL/min/1.73m3
• Positive hepatitis B surface antigen, or hepatitis C antibody or HIV antibody at screening
• FEV1 ≤39% or has lung score of 3

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org